Carbidopa/levodopa (WD-1603) vs Parcopa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Carbidopa/levodopa (WD-1603)

Developed by Hong Kong WD Pharmaceutical Co., Limited

Phase 2 in Parkinson's Diseasesmall molecule
Partial signal

NCT05036473 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.

Reported efficacy

To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)

Result source: NCT05036473

Parcopa

Rights held by UCB; US product discontinued

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT00139867 · Phase 3 · completed

The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)

Result source: NCT00139880

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointCarbidopa/​levodopa (WD-1603)Parcopa
OFF time, change—Not reported—Not posted · NCT00139880
ON time without troublesome dyskinesia, change—Not reported—Not posted · NCT00139880
UPDRS Part III, change—Not reported—Not posted · NCT00139880
MDS-UPDRS Part II, change—Not reported—Not posted · NCT00139880

OFF time, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Parcopa
—Not posted · NCT00139880

ON time without troublesome dyskinesia, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Parcopa
—Not posted · NCT00139880

UPDRS Part III, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Parcopa
—Not posted · NCT00139880

MDS-UPDRS Part II, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Parcopa
—Not posted · NCT00139880
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carbidopa/levodopa (WD-1603): 0 of 4 rows · Parcopa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCarbidopa/​levodopa (WD-1603)Parcopa
Dropout rate—
—a
NCT00590122 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs—
—a
NCT00590122 · Phase 4 · registry result, not featured evidence
Serious AEs—
0%a
NCT00590122 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs—
a
dyskinesia 5%
nausea 0%
NCT00590122 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Carbidopa/levodopa (WD-1603)

MDS-UPDRS II III -6.7 score @ 3.857142857142857wk
absolute change · score
No placebo or comparator arm
NCT05036473 · Phase 2 · sponsor-reported, not registry data
show 2 more results
-8.5 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data
-13.6 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data

Parcopa

Time to 'ON Response 23.9 vs 28.5 Carbidopa/Levodopa minutes
absolute value · minutes
NCT00590122 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · Parcopa's landscape